Filing Flows › Regenxbio (RGNX) › Q3 2026
Regenxbio (RGNX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Regenxbio (RGNX) reported revenue of $9.2M for the third quarter 2026 (Q3 2026), -69% from a year earlier and -92% from the quarter before. Operating margin was -387.8%, net loss $40.7M (444.6% of revenue).
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | -92% | -69% |
| Operating profit | −$35.5M | -221% | — |
| Net earnings | −$40.7M | -279% | — |
| Operating cash flow | $38.6M | — | — |
| Free cash flow | $38.4M | — | — |
What changed
Revenue was $9.2M in Q3 2026, down 69% year over year and down 92% from the previous quarter. Nippon Shinyaku Services was the largest line at 36% of revenue. Zolgensma Royalties lost $21.2M year over year (down 90%), 103% of the total change.
Operating costs exceeded revenue by $35.5M, an operating margin of -387.8%. Total costs fell 46% while revenue fell 69%. The quarter ended with a net loss of $40.7M, after a profit of $22.7M the previous quarter.
Operating cash flow was $38.6M. Non-cash charges added back $3.5M of depreciation and amortization and $8.1M of share-based compensation. Working capital and other items added $67.7M. Capital expenditures of $194K left free cash flow of $38.4M.
Questions
What was Regenxbio's revenue in the third quarter 2026?
Regenxbio (RGNX) reported revenue of $9.2M for the third quarter 2026 (Q3 2026), -69% from a year earlier and -92% from the quarter before.
Was Regenxbio profitable in the third quarter 2026?
Operating loss was $35.5M (-387.8% of revenue) and net loss $40.7M.
Source: Regenxbio 10-Q on SEC EDGAR.